Joe Gantoss’ Post

Recently, Inventiva announced positive results of its interim analysis of the Phase II, Proof-of-Concept clinical trial, LEGEND, evaluating lanifibranor in combination with empagliflozin in patients with MASH/NASH and poorly controlled Type 2 Diabetes (T2D). The study achieved the primary efficacy endpoint. Lanifibranor is an orally-available small molecule pan PPAR agonist with a -wellbalanced- activation of PPARα and PPARδ, and a partial activation of PPARγ. Lanifibranor acts to induce anti fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body. Chemenu team is always committed to developing more compounds for drug discovery. Here come the related building blocks we can provide: https://lnkd.in/gxNGFuzH 👇 #Chemenu #Inventiva #LEGEND #lanifibranor #empagliflozin #MASH/NASH #Type2Diabetes #endpoint #PPAR #antifibrotic #anti-inflammatory #vascularandmetabolicchanges #drugdiscovery #buildingblocks

I have exciting news to share from Amrit - a Partex Companys Parent Company! https://lnkd.in/eND2u96P EY and Innoplexus - a Partex Company have collaborated to develop an innovative approach for assessing the growth potential of biopharma companies in specific therapeutic areas or medical technology fields. In November 2022, the first report on innovation in autoimmune therapy was published, "Innovation in biopharma: a new way of assessing companies’ potential for growth", which provided a comprehensive analysis of more than 1,100 clinical trials across 17 significant autoimmune indications. This refreshed report focuses on clinical trials that started or were in progress between the end of March 2022 and the beginning of July 2023. A comprehensive analysis of 819 distinct trials, categorized by indication and intervention, was conducted to assess the likelihood of clinical success in each phase. In addition, interventions were ranked by how innovative they were. In this refreshed report, there are 24 new entrants in the list of Top 50 sponsors, indicating the rapidly changing landscape and fierce clinical competition in autoimmune indications. This publication reflects our commitment to fostering innovation and delivering real solutions to those in need. We are proud to be part of this important work that aims not only to address current treatment gaps but also to inspire future breakthroughs in the field. #AutoimmuneDisease #HealthcareInnovation #Biotech #Pharma #EYParthenon #Innoplexus #PartexCompany #ClinicalResearch

#NewAnnouncement #newmilestone #psoriasiscare Scinai Immunotherapeutics Ltd. is delighted to share that it received positive feedback from scientific advice with the Paul-Ehrlich-Institut (PEI) on its plans to advance our anti-IL-17A/F nanoAb (SCN-1) for the treatment of patients with mild to moderate plaque psoriasis to Phase 1/2a #clinical_trial. This first-in-human trial will utilize intralesional injections, a pioneering approach in psoriasis care. It will be tested in patients suffering from psoriasis, which means faster timelines for in human proof of concept. In addition, the PEI responded favorably to our request to test both the placebo and the test drug on the same patient potentially reducing the number of participants needed for the trial and its overall costs. The PEI commented that SCN-1's manufacturing process is robust, with controls and specifications meeting the required standards. We are scheduled to begin the Phase 1/2a study in the latter half of 2025 and look forward to disclosing the results in 2026. As we anticipate the upcoming data, we are honored to contribute to this significant breakthrough in psoriasis treatment. #Innovation #biotech #biopharma #clinicaltrials

𝗚𝗮𝗶𝗻 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝘁𝗼𝗽𝗹𝗶𝗻𝗲 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗳𝗿𝗼𝗺 𝗣𝗵𝗮𝘀𝗲 𝗜 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲𝗶𝗿 𝗱𝗿𝘂𝗴 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲 𝗳𝗼𝗿 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻'𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲. The trial, involving 72 healthy volunteers, demonstrated that GT-02287 is safe and well-tolerated across all dose levels, with no serious adverse events reported. This brain-penetrant small molecule aims to address Parkinson’s symptoms by reducing neuroinflammation, and with positive safety data Gain Therapeutics plans to initiate a Phase II trial in Parkinson’s patients by Q4 2024, aiming to further validate the drug’s efficacy and mechanism. #Pharma #ClinicalTrials #ParkinsonsDisease #Innovation #DrugDevelopment #GainTherapeutics

𝐍𝐨𝐯𝐞𝐥 𝐩𝐞𝐩𝐭𝐢𝐝𝐞-𝐛𝐚𝐬𝐞𝐝 𝐢𝐧𝐡𝐚𝐥𝐚𝐭𝐢𝐨𝐧 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐡𝐞𝐚𝐫𝐭 𝐟𝐚𝐢𝐥𝐮𝐫𝐞   Heart failure affects millions of people worldwide and challenges regarding successful application of biologics in the clinical setting still remain. A team of researchers involving PD Dr Alessio Alogna aimed to address the lack of effective treatments for heart failure by testing a new delivery method. For this they used a unique technology called LungToHeartNIM to deliver a peptide targeting a specific heart failure mechanism. The inhaled therapy significantly improved heart function, reversed heart remodelling and reduced lung congestion in the pig model without causing any adverse effects. This suggests that the LungToHeartNIM technology could be a breakthrough treatment for heart failure patients by effectively delivering therapeutic peptides directly to the heart. "The general tolerability and the positive effects could fundamentally change the treatment of patients with heart failure," so Alogna. 🐖❤️🫁   Congratulations on this scientific breakthrough! 👨🔬🔬   The publication was named DZHK 𝐏𝐚𝐩𝐞𝐫 𝐨𝐟 𝐭𝐡𝐞 𝐌𝐨𝐧𝐭𝐡 February 2024. Read it here: https://lnkd.in/eJZtec-T Link to the news on the DZHK website: https://lnkd.in/eqf8vh3x Deutsches Herzzentrum der Charité (DHZC) #heartfailure #therapy #LungToHeartNIM #lung #heart

A single #intraarticular injection of Nano-PAZII —a #nanoparticle-based formulation of #Pazopanib, an FDA-approved anticancer drug that targets both #VEGFR1 and #VEGFR2— has beneficial effects at different stages of #osteoarthritis (OA) disease progression by rapidly reducing knee joint #pain, with sustained analgesic effects and marked suppression of #cartilage degeneration for months. Furthermore, Nano-PAZII does not affect opioid-related addictive reward behaviors in preclinical murine OA models. These properties collectively suggest that Nano-PAZII has potential as a novel disease-modifying OA drug, providing a promising therapeutic strategy for pain treatment and management. 🔗https://lnkd.in/d8FtsGjq

Neurotech is featured in Stockhead's Investor Guide, highlighting the thriving Australian healthcare and biotech innovation sector.   In the spotlight, Neurotech stands proud alongside industry leaders like Neuren Pharmaceuticals. Our work on NTI164, a broad spectrum cannabinoid drug therapy for Rett syndrome, shows promising results, with significant improvements in communication skills and mental alertness in Phase I/II clinical trials.   Executive Director Dr. Thomas Duthy emphasises the potential for NTI164 to provide a superior treatment option, with fewer side effects, and the possibility of it being used in combination with existing therapies.   We’re also advancing clinical programs for autism and PANDAS/PANS, showing meaningful improvements and forging ahead with our clinical development pipeline.   Read the full article in Stockhead's Investor Guide to learn more about our journey.   👉 Read the Article https://lnkd.in/gppgdwNK   #NeurotechInternational #NTI #Biotech #HealthcareInnovation #RareDiseases #CannabinoidTherapies #RettSyndrome #Autism #PANDASPANS #ClinicalTrials #InvestInHealth

🚀 Forecasting the Future of PAH Therapeutics: Market Trends and Developments The Pulmonary Arterial Hypertension (PAH) treatment landscape is seeing exciting changes as established therapies continue to perform and new options advance through development. 📊💊 Projections show sustained growth for therapies like macitentan and treprostinil, while new entrants like sotatercept and selexipag (currently in Phase III) have the potential to reshape the treatment paradigm. One standout is sotatercept by Merck, anticipated to see a substantial rise in sales from $552M in 2024 to over $6B by 2030. 📈💡 Additionally, promising new therapies like brilaroxazine hydrochloride and ralinepag XR in early development stages underscore the industry’s dedication to innovation and improved patient outcomes. As PAH treatment options evolve, it’s clear that the future holds exciting opportunities for patients and healthcare providers alike! 💡💉 Interactive Graph: https://lnkd.in/g6R_bKHE #PAH #PulmonaryArterialHypertension #HealthcareInnovation #Biopharma #Therapeutics #DrugDevelopment

Why do patients experience withdrawal after opiate use? Opiates, including codeine, fentanyl, methadone, and heroin, can lead to drug tolerance, meaning that patients require more or a more potent drug to gain the original effects. This dependence can make it challenging, if possible, to stop independently, which is never recommended. Speranza Therapeutics S. T. Genesis device empowers patients to make informed decisions about their treatment and Medication Assisted Therapies. #addictionmedicine #mat #opioidcrisis

Have you spotted our contribution to #RadiotheranosticsToday from Oncidium foundation?   In this article, we elaborate on the use of Phase 0 clinical trials in the development of radiopharmaceuticals. Check it out here: #radiopharmaceuticals #drugdevelopment #clinicaltrials #phase0 #molecularimaging